Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Despite showing a progression-free survival (PFS) benefit, oncologists advise against the SERENA-6 strategy of switching therapy upon detecting an ESR1 mutation before clinical progression. The lack of overall survival data, flawed trial comparison (PFS vs PFS2), and significant cost burdens make this approach premature for clinical practice.
Related Insights
The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.
A study switching therapy based on ctDNA-detected ESR1 mutations revealed patients felt significantly better after the switch, even without visible tumor progression on scans. This counterintuitive finding suggests molecular progression has a subclinical impact on quality of life, supporting proactive, biomarker-driven treatment changes before patients clinically deteriorate.
ODAC's critique of the SERENA-6 trial, focusing on immature overall survival (OS) data, contrasts sharply with previous landmark approvals like CDK4/6 inhibitors, which were approved without OS data. This suggests innovative, biomarker-adaptive trials may face a higher, potentially unfair, regulatory bar.
The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.
The rapid evolution of clinical evidence is reflected in ASCO guidelines. In just one year (2022 to 2023), recommendations for ESR1 testing in HR+ metastatic breast cancer changed from having insufficient data to recommending routine testing upon progression, highlighting the pace of change in oncology.
SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.
Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.
The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.
The SERENA-6 trial tested a hypothesis rooted in evolutionary biology: intervening when a resistance mutation (ESR1) first appears in ctDNA, while the clone is small and less diverse, rather than waiting for clinical progression. This proactive approach aims to control resistance before it becomes dominant and harder to treat.
The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.